Xellar Biosystems

Xellar Biosystems (耀速科技) is a next-generation AI-driven organ-chip platform company that has raised multiple funding rounds since its angel stage, including a 100-million-yuan angel+ round led by TriApex with follow-ons from Zhenshun Investment and Tiantu Capital in mid-2024 , a new tens-of-millions yuan round in April 2025 , and a Series A of over 200 million RMB in early 2026 that ZhenFund joined at the angel stage in 2022 . The company has published research in *Nature* sub-journals through collaborations with institutions including the Chinese Academy of Sciences and Harvard Medical School , won L'Oréal's 2024 Big Bang Award , and partnered with Pfizer to launch a next-generation AI image decision engine in mid-2025 . Its stated focus is building biological intelligence infrastructure centered on humanized models and mechanism research, scaling organ-chip disease models, and driving AI platforms with proprietary 3D wet-lab data .